HCPLive Network

Including Newer Biomarkers in Testing Improves Death Prediction in Chronic Kidney Disease

Though patients with chronic kidney disease (CKD) have variable risks of death, the population risk prediction tools that are currently available perform poorly. 
 
To establish more satisfactory prediction models, Adeera Levin, MD, and colleagues from the Division of Nephrology of the Department of Medicine of the University of British Columbia undertook the Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT) — a large, prospective cohort study that began in 2008 — and reported their findings at Kidney Week 2013, the American Society of Nephrology's annual  meeting held November 5-10, 2013, in Atlanta, GA.
 
In that study, 2,544 CKD patients referred from 25 rural, urban, academic, and non-academic centers throughout Canada underwent baseline newer biomarker (NMB) tests, which included asymmetric dimethylarginine (ADMA), high sensitivity C-reactive protein (hsCRP), interleukin 6, N-terminal pro-brain natriuretic peptide (NTproBNP), troponin I, transforming growth factor beta 1 (TGFβ1), cystatin C, and fibroblast growth factor (FGF23). The mean age of the cohort was 68 years old, while the median estimated glomerular filtration rate (eGFR) was 28ml/min/1.73m2. According to the researchers, 48% of patients had diabetes,  and 15.5% died during the 3-year follow-up.
 
Patients were followed for 3 years at 6-month intervals and annually monitored for traditional biomarkers, such as eGFR, urine albumin creatinine ratio (uACR), hemoglobin (Hgb), and phosphate and albumin. The researchers also performed the aforementioned NMB tests after collecting blood and urine samples on schedule.
 
To investigate whether including NBMs improve the prediction of death risk in CKD patients to a greater extent than conventional clinical, demographic, and laboratory predictors, the researchers compared discrimination (C statistic) and classification (NRI) of proportional hazard models based on conventional markers versus a combination of conventional and NBM markers.
 
After adjusting for base predictors, they found that the biomarker NTproBNP was the best predictor of mortality (NRI=8.9; 95% confidence interval [CI]: 3.3-17.4), followed by hsCRP (NRI=4.5; 95% CI: 1.3-9.6) and FGF23 (NRI=3.1; 95% CI: 0.4-11.4).
 
While the authors found that including NBMs in risk prediction models significantly improves the precision of death prediction in CKD patients, they noted that their approach needs to be validated with further testing.
 
The authors disclosed support from Ortho Janssen.


Further Reading
High-intensity statin therapy can alter the progressive nature of diabetic atherosclerosis, according to a study published online Sept. 4 in Diabetes Care.
A new implantable eye device might make reading glasses a thing of the past, according to research presented at the annual meeting of the American Academy of Ophthalmology, held from Oct. 18 to 21 in Chicago.
Interim study results presented at ACG 2014 indicate that treatment with vedolizumab safely and effectively maintains long-term clinical remission and response in patients with Crohn’s disease and ulcerative colitis.
A man's caffeine intake could hamper the success of a couple's infertility treatment, while mild alcohol use by would-be fathers might help boost the odds of pregnancy through in vitro fertilization (IVF), according to research presented at the annual meeting of the American Society for Reproductive Medicine, held from Oct. 18 to 22 in Honolulu.
A child receives the wrong medication or the wrong dosage every 8 minutes in the United States, according to a study published online Oct. 20 in Pediatrics.
A three-minute diagnostic assessment (3D-Confusion Assessment Method) has high sensitivity and specificity for identifying delirium, according to a study published in the Oct. 21 issue of the Annals of Internal Medicine.
In the era of rapidly improving cure rates for hepatitis C infection, has the importance of staging as part of treatment diminished?
More Reading
High-intensity statin therapy can alter the progressive nature of diabetic atherosclerosis, according to a study published online Sept. 4 in Diabetes Care.